COGT

COGT

USD

Cogent Biosciences Inc. Common Stock

$14.130-1.110 (-7.283%)

السعر في الوقت الحقيقي

Healthcare
التكنولوجيا الحيوية
الولايات المتحدة

مخطط الأسعار

Loading Chart...

المقاييس الرئيسية

مقاييس السوق
أساسيات الشركة
إحصاءات التداول

مقاييس السوق

الافتتاح

$15.240

الأعلى

$15.870

الأدنى

$13.980

الحجم

0.44M

أساسيات الشركة

القيمة السوقية

2.0B

الصناعة

التكنولوجيا الحيوية

البلد

United States

إحصاءات التداول

متوسط الحجم

1.89M

البورصة

NMS

العملة

USD

نطاق 52 أسبوعاً

الأدنى $3.72الحالي $14.130الأعلى $17.15

أخبار ذات صلة

Analyst Upgrades

HC Wainwright & Co. Reiterates Buy on Cogent Biosciences, Maintains $21 Price Target

HC Wainwright & Co. analyst Robert Burns reiterates Cogent Biosciences with a Buy and maintains $21 price target.

عرض المزيد
HC Wainwright & Co. Reiterates Buy on Cogent Biosciences, Maintains $21 Price Target
GlobeNewswire

Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2025 Financial Results

Phase 3 PEAK results in 2nd-line GIST patients expected in November; pivotal APEX results in AdvSM patients expected in December Breakthrough Therapy Designation granted for bezuclastinib; New Drug Application (NDA)

عرض المزيد
Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2025 Financial Results
GlobeNewswire

Cogent Biosciences Announces Multiple Presentations at the 67th Annual American Society of Hematology (ASH) Meeting

SUMMIT data for bezuclastinib in NonAdvSM selected for two oral presentations which will describe its best-in-class potential Novel JAK2 V617F mutant-selective inhibitor announced as Cogent's newest preclinical program;

عرض المزيد
Cogent Biosciences Announces Multiple Presentations at the 67th Annual American Society of Hematology (ASH) Meeting
GlobeNewswire

Cogent Biosciences Announces KRAS Poster Presentation at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

WALTHAM, Mass. and BOULDER, Colo., Oct. 24, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (NASDAQ:COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today

عرض المزيد
Cogent Biosciences Announces KRAS Poster Presentation at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Analyst Upgrades

JP Morgan Maintains Overweight on Cogent Biosciences, Raises Price Target to $44

JP Morgan analyst Anupam Rama maintains Cogent Biosciences with a Overweight and raises the price target from $30 to $44.

عرض المزيد
JP Morgan Maintains Overweight on Cogent Biosciences, Raises Price Target to $44

ابق على اطلاع

تعيين تنبيهات الأسعار، الحصول على تحديثات تحليل الذكاء الاصطناعي وأخبار السوق في الوقت الحقيقي.